Halozyme Therapeutics Reports Q2 2026 Quarterly Results

What Happened
Halozyme Therapeutics, Inc. announced on August 6, 2026 that it issued a press release reporting its financial results for the quarter ended June 30, 2026. The company furnished the press release as Exhibit 99.1 to the Form 8-K, which was signed by Darren Snellgrove, Executive Vice President and Chief Financial Officer.

Key Details

• Event reported under Item 2.02: Results of Operations and Financial Condition.
• Press release dated August 6, 2026 attached as Exhibit 99.1 to the 8-K.
• Quarter reported: second quarter ended June 30, 2026.
• Form 8-K was signed and dated August 6, 2026 by CFO Darren Snellgrove.

Why It Matters
Quarterly results provide updated information on Halozyme’s earnings, revenue and financial condition that investors use to assess company performance and set expectations. This 8-K signals that the company has publicly released its Q2 2026 results; investors should read the attached press release (Exhibit 99.1) and the company’s subsequent quarterly filings (e.g., Form 10-Q) for full financial details and metrics that drive valuation and trading decisions.